##### Table of Contents



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
 FORM 10-Q
 þ
    
    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 For the quarterly period ended June 30, 2009
 or
 o
    
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 For the transition period from to
 Commission File Number: 0-28298
 ONYX PHARMACEUTICALS, INC.
  Delaware
    
    94-3154463(State or other jurisdiction of 
incorporation or organization)
    
    (I.R.S. Employer ID Number)
 
 
 þ o
 o o
  Large accelerated filer þ
    
    Accelerated filer o
    
    Non-accelerated filer o
    
    Smaller reporting company o(Do not check if a smaller reporting company)
 o þ




---



##### 



INDEX
 PagePART I: FINANCIAL INFORMATION
    
    
    3Item 1.Financial Statements (Unaudited)
    
    
    3Condensed Balance Sheets  June 30, 2009 and December 31, 2008
    
    
    3Condensed Statements of Operations  Three and six months ended June 30, 2009 and 2008
    
    
    4Condensed Statements of Cash Flows  Six months ended June 30, 2009 and 2008
    
    
    5Notes to Condensed Financial Statements
    
    
    6Item 2.Managements Discussion and Analysis of Financial Condition and Results of Operations
    
    
    13Item 3.Quantitative and Qualitative Disclosures About Market Risk
    
    
    17Item 4.Controls and Procedures
    
    
    18PART II: OTHER INFORMATION
    
    
    19Item 1.Legal Proceedings
    
    
    19Item 1A.Risk Factors
    
    
    20Item 2.Unregistered Sales of Equity Securities and Use of Proceeds
    
    
    35Item 3.Defaults Upon Senior Securities
    
    
    35Item 4.Submission of Matters to a Vote of Security Holders
    
    
    35Item 5.Other Information
    
    
    36Item 6.Exhibits
    
    
    36SIGNATURES
    
    
    38EX-31.1EX-31.2EX-32.1
  2




---



##### Table of Contents



PART I: FINANCIAL INFORMATION
 
 Item 1.
    
    Financial Statements (Unaudited)
 
 CONDENSED BALANCE SHEETS
 June 30,
    
    
    December 31,2009
    
    
    2008(Unaudited)
    
    
    (Note 1)(In thousands)ASSETSCurrent assets:Cash and cash equivalents
    
    $
    75,449
    
    
    $
    235,152Marketable securities, current
    
    
    356,293
    
    
    
    183,272Receivable from collaboration partner
    
    
    46,380
    
    
    
    35,836Prepaid expenses and other current assets
    
    
    7,145
    
    
    
    7,799Total current assets
    
    
    485,267
    
    
    
    462,059Marketable securities, non-current
    
    
    37,759
    
    
    
    39,622Property and equipment, net
    
    
    2,724
    
    
    
    3,363Other assets
    
    
    4,740
    
    
    
    4,723Total assets
    
    $
    530,490
    
    
    $
    509,767LIABILITIES AND STOCKHOLDERS EQUITYCurrent liabilities:Accounts payable
    
    $
    202
    
    
    $
    93Advance from collaboration partner
    
    
    3,081
    
    
    
    16,633Accrued liabilities
    
    
    5,113
    
    
    
    4,523Accrued clinical trials and related expenses
    
    
    7,948
    
    
    
    6,041Accrued compensation
    
    
    5,023
    
    
    
    6,014Total current liabilities
    
    
    21,367
    
    
    
    33,304Deferred rent and lease incentives
    
    
    1,074
    
    
    
    1,263Commitments and contingenciesStockholders equity:Common stock
    
    
    57
    
    
    
    57Additional paid-in capital
    
    
    966,826
    
    
    
    950,628Receivable from stock option exercises
    
    
    (198
    )
    
    
    (455
    )Accumulated other comprehensive loss
    
    
    (1,365
    )
    
    
    (4,320
    )Accumulated deficit
    
    
    (457,271
    )
    
    
    (470,710
    )Total stockholders equity
    
    
    508,049
    
    
    
    475,200Total liabilities and stockholders equity
    
    $
    530,490
    
    
    $
    509,767
  3




---



##### Table of Contents



CONDENSED STATEMENTS OF OPERATIONS
 Three Months Ended
    
    
    Six Months EndedJune 30,
    
    
    June 30,2009
    
    
    2008
    
    
    2009
    
    
    2008(In thousands, except per share amounts)Revenue:Revenue from collaboration agreement
    
    $
    60,219
    
    
    $
    45,072
    
    
    $
    113,936
    
    
    $
    93,927Total operating revenue
    
    
    60,219
    
    
    
    45,072
    
    
    
    113,936
    
    
    
    93,927Operating Expenses:Research and development
    
    
    28,022
    
    
    
    23,498
    
    
    
    56,842
    
    
    
    42,052Selling, general and administrative
    
    
    23,507
    
    
    
    19,822
    
    
    
    45,459
    
    
    
    39,667Total operating expenses
    
    
    51,529
    
    
    
    43,320
    
    
    
    102,301
    
    
    
    81,719Income
from operations
    
    
    8,690
    
    
    
    1,752
    
    
    
    11,635
    
    
    
    12,208Investment income, net
    
    
    972
    
    
    
    2,662
    
    
    
    2,092
    
    
    
    7,933Provision (benefit) for income taxes
    
    
    288
    
    
    
    (60
    )
    
    
    288
    
    
    
    249Net income
    
    $
    9,374
    
    
    $
    4,474
    
    
    $
    13,439
    
    
    $
    19,892Net income per share:Basic
    
    $
    0.16
    
    
    $
    0.08
    
    
    $
    0.24
    
    
    $
    0.36Diluted
    
    $
    0.16
    
    
    $
    0.08
    
    
    $
    0.24
    
    
    $
    0.35Shares used in computing net income per share:Basic
    
    
    56,890
    
    
    
    55,675
    
    
    
    56,803
    
    
    
    55,531Diluted
    
    
    57,110
    
    
    
    56,472
    
    
    
    57,178
    
    
    
    56,534
  4




---



##### Table of Contents



CONDENSED STATEMENTS OF CASH FLOWS
 Six Months Ended June 30,2009
    
    
    2008(In thousands)Cash flows from operating activities:Net income
    
    $
    13,439
    
    
    $
    19,892Adjustments to reconcile net income to net cash
provided by operating activities:Realized gains on sales of short-term marketable securities
    
    
    
    
    
    
    (483
    )Depreciation and amortization
    
    
    742
    
    
    
    672Stock-based compensation
    
    
    10,790
    
    
    
    9,884Excess tax benefit from stock-based awards
    
    
    (2
    )
    
    
    Changes in operating assets and liabilities:Receivable from collaboration partner
    
    
    (10,544
    )
    
    
    (25,591
    )Prepaid expenses and other current assets
    
    
    656
    
    
    
    (3,115
    )Other assets
    
    
    (17
    )
    
    
    7Accounts payable
    
    
    109
    
    
    
    856Accrued liabilities
    
    
    590
    
    
    
    1,653Accrued clinical trials and related expenses
    
    
    1,907
    
    
    
    2,119Accrued compensation
    
    
    (991
    )
    
    
    (1,981
    )Deferred rent and lease incentives
    
    
    (189
    )
    
    
    47Net cash provided by operating activities
    
    
    16,490
    
    
    
    3,960Cash flows from investing activities:Purchases of marketable securities
    
    
    (316,358
    )
    
    
    (208,558
    )Sales of marketable securities
    
    
    38,155
    
    
    
    82,916Maturities of marketable securities
    
    
    110,000
    
    
    
    198,415Capital expenditures
    
    
    (103
    )
    
    
    (55
    )Net cash provided by (used in) investing activities
    
    
    (168,306
    )
    
    
    72,718Cash flows from financing activities:Purchases of treasury stock
    
    
    (18
    )
    
    
    (529
    )Advance from (payment to) collaboration partner
    
    
    (13,552
    )
    
    
    (8,862
    )Net proceeds from issuances of common stock
    
    
    5,681
    
    
    
    8,007Excess tax benefit from stock-based awards
    
    
    2
    
    
    
    Net cash used in financing activities
    
    
    (7,887
    )
    
    
    (1,384
    )Net increase (decrease) in cash and cash equivalents
    
    
    (159,703
    )
    
    
    75,294Cash and cash equivalents at beginning of period
    
    
    235,152
    
    
    
    161,653Cash and cash equivalents at end of period
    
    $
    75,449
    
    
    $
    236,947
  5




---



##### Table of Contents



NOTES TO CONDENSED FINANCIAL STATEMENTS
June 30, 2009
(Unaudited)
 Note 1. Basis of Presentation
   Note 2. Revenue from Collaboration Agreement
      6




---



##### Table of Contents



Three Months Ended June 30,
    
    
    Six Months Ended June 30,2009
    
    
    2008
    
    
    2009
    
    
    2008(In thousands)Onyxs share of collaboration commercial profit
    
    $
    53,501
    
    
    $
    38,206
    
    
    $
    101,049
    
    
    $
    82,803Reimbursement of Onyxs shared marketing expenses
    
    
    5,344
    
    
    
    6,028
    
    
    
    10,736
    
    
    
    10,286Royalty revenue
    
    
    1,374
    
    
    
    838
    
    
    
    2,151
    
    
    
    838Revenue from collaboration agreement
    
    $
    60,219
    
    
    $
    45,072
    
    
    $
    113,936
    
    
    $
    93,927
 Note 3. Fair Value Measurements
   
    
    Level 1, defined as observable inputs such as quoted prices for identical assets in
active markets;
 
    
    Level 2, defined as inputs other than quoted prices in active markets that are either
directly or indirectly observable; and
 
    
    Level 3, defined as unobservable inputs in which little or no market data exists,
therefore requiring management to develop its own assumptions based on best estimates of
what market participants would use in pricing an asset or liability at the reporting date.
 7




---



##### Table of Contents



As of June 30, 2009
    
    
    As of December 31, 2008(In thousands)Level 1
    
    
    Level 2
    
    
    Level 3
    
    
    Total
    
    
    Level 1
    
    
    Level 2
    
    
    Level 3
    
    
    TotalMoney market funds
    
    $
    46,029
    
    
    $
    
    
    
    $
    
    
    
    $
    46,029
    
    
    $
    113,832
    
    
    $
    
    
    
    $
    
    
    
    $
    113,832Commercial paper
    
    
    
    
    
    
    40,029
    
    
    
    
    
    
    
    40,029
    
    
    
    
    
    
    
    109,866
    
    
    
    
    
    
    
    109,866Auction rate securities
    
    
    
    
    
    
    200
    
    
    
    37,759
    
    
    
    37,959
    
    
    
    
    
    
    
    
    
    
    
    39,622
    
    
    
    39,622U.S. government agencies
    
    
    
    
    
    
    132,430
    
    
    
    
    
    
    
    132,430
    
    
    
    
    
    
    
    143,376
    
    
    
    
    
    
    
    143,376U.S. treasury bills
    
    
    210,630
    
    
    
    
    
    
    
    
    
    
    
    210,630
    
    
    
    49,993
    
    
    
    
    
    
    
    
    
    
    
    49,993Total
    
    $
    256,659
    
    
    $
    172,659
    
    
    $
    37,759
    
    
    $
    467,077
    
    
    $
    163,825
    
    
    $
    253,242
    
    
    $
    39,622
    
    
    $
    456,689
  Auction Rate SecuritiesSix Months EndedJune 30, 2009
    
    
    June 30, 2008(In thousands)Fair value at beginning of period
    
    $
    39,622
    
    
    $
    50,000Redemptions
    
    
    (5,100
    )
    
    
    Transfer to Level 2
    
    
    (200
    )
    
    
    (5,000
    )Change in valuation
    
    
    3,437
    
    
    
    (1,170
    )Fair value at end of period
    
    $
    37,759
    
    
    $
    43,830
  Note 4. Marketable Securities
  8




---



##### Table of Contents



June 30, 2009Adjusted
    
    
    Unrealized
    
    
    Unrealized
    
    
    EstimatedCost
    
    
    Gains
    
    
    Losses
    
    
    Fair Value(In thousands)Agency bond investments:Current
    
    $
    342,485
    
    
    $
    580
    
    
    $
    (5
    )
    
    $
    343,060Total agency bond investments
    
    
    342,485
    
    
    
    580
    
    
    
    (5
    )
    
    
    343,060Corporate debt investments:Current
    
    
    40,228
    
    
    
    1
    
    
    
    
    
    
    
    40,229Non-current
    
    
    39,700
    
    
    
    
    
    
    
    (1,941
    )
    
    
    37,759Total corporate investments
    
    
    79,928
    
    
    
    1
    
    
    
    (1,941
    )
    
    
    77,988Total available-for-sale marketable securities
    
    $
    422,413
    
    
    $
    581
    
    
    $
    (1,946
    )
    
    $
    421,048
 December 31, 2008Adjusted
    
    
    Unrealized
    
    
    Unrealized
    
    
    EstimatedCost
    
    
    Gains
    
    
    Losses
    
    
    Fair Value(In thousands)Agency bond investments:Current
    
    $
    132,319
    
    
    $
    1,054
    
    
    $
    (4
    )
    
    $
    133,369Total agency bond investments
    
    
    132,319
    
    
    
    1,054
    
    
    
    (4
    )
    
    
    133,369Corporate debt investments:Current
    
    
    49,903
    
    
    
    
    
    
    
    
    
    
    
    49,903Non-current
    
    
    45,000
    
    
    
    
    
    
    
    (5,378
    )
    
    
    39,622Total corporate investments
    
    
    94,903
    
    
    
    
    
    
    
    (5,378
    )
    
    
    89,525Total available-for-sale marketable securities
    
    $
    227,222
    
    
    $
    1,054
    
    
    $
    (5,382
    )
    
    $
    222,894
  Note 5. Other Long-Term Assets
  Note 6. Advance from Collaboration Partner
  9




---



##### Table of Contents



Note 7. Stock-Based Compensation
  Employee Stock Plans
  Valuation Assumptions
  Three Months Ended
    
    Six Months EndedJune 30,
    
    June 30,2009
    
    2008
    
    2009
    
    2008Stock Option Plans:Risk-free interest rate
    
    
    1.96%
    
    
    
    2.89%
    
    
    
    1.81%
    
    
    
    2.85%Expected life
    
    4.3 years

    
    4.4 years

    
    4.3 years

    
    4.4 yearsExpected volatility
    
    
    62%
    
    
    
    64%
    
    
    
    66%
    
    
    
    64%Expected dividends
    
    None

    
    None

    
    None

    
    NoneWeighted average option fair value
    
    
    $12.59
    
    
    
    $18.42
    
    
    
    $15.33
    
    
    
    $17.09Stock Bonus Awards:Expected life
    
    3 years

    
    3 years

    
    3 years

    
    3 yearsExpected dividends
    
    None

    
    None

    
    None

    
    NoneWeighted average fair value per share
    
    
    $25.23
    
    
    
    $35.67
    
    
    
    $28.88
    
    
    
    $30.77ESPP:Risk-free interest rate
    
    
    0.26%
    
    
    
    3.34%
    
    
    
    0.26%
    
    
    
    3.34%Expected life
    
    6 months

    
    6 months

    
    6 months

    
    6 monthsExpected volatility
    
    
    66%
    
    
    
    64%
    
    
    
    66%
    
    
    
    64%Expected dividends
    
    None

    
    None

    
    None

    
    NoneWeighted average shares fair value
    
    
    $10.42
    
    
    
    $17.18
    
    
    
    $10.42
    
    
    
    $17.18
 10




---



##### Table of Contents



Note 8. Income Taxes
   Note 9. Net Income per Share
  Note 10. Comprehensive Income
  Three Months Ended
    
    
    Six Months EndedJune 30,
    
    
    June 30,2009
    
    
    2008
    
    
    2009
    
    
    2008(In thousands)
    
    
    (In thousands)Net income  as reported
    
    $
    9,374
    
    
    $
    4,474
    
    
    $
    13,439
    
    
    $
    19,892Other comprehensive income (loss):Change in unrealized gain (loss) on available-for-sale securities
    
    
    1,482
    
    
    
    405
    
    
    
    2,955
    
    
    
    (1,439
    )Comprehensive income
    
    $
    10,856
    
    
    $
    4,879
    
    
    $
    16,394
    
    
    $
    18,453
  Three Months Ended
    
    
    Six Months EndedJune 30,
    
    
    June 30,2009
    
    
    2008
    
    
    2009
    
    
    2008(In thousands)
    
    
    (In thousands)Increase (decrease) in unrealized gain (loss) on available-for-sale securities
    
    $
    1,482
    
    
    $
    405
    
    
    $
    2,955
    
    
    $
    (1,922
    )Reclassification adjustment for net gains on available-for-sale securities
including in net income
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    483Change in unrealized gain (loss) on available-for-sale securities
    
    $
    1,482
    
    
    $
    405
    
    
    $
    2,955
    
    
    $
    (1,439
    )
 11




---



##### Table of Contents



Note 11. Subsequent Events
  Note 12. Related Party Transactions
  12




---



##### Table of Contents



Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations
 The following Managements Discussion and Analysis of Financial Condition and Results of Operations
contains forward-looking statements that involve risks and uncertainties. We use words such as
may, will, expect, anticipate, estimate, intend, plan, predict, potential,
believe, should and similar expressions to identify forward-looking statements. These
statements appearing throughout our Form 10-Q are statements regarding our intent, belief, or
current expectations, primarily regarding our operations. You should not place undue reliance on
these forward-looking statements, which apply only as of the date of this Form 10-Q. Our actual
results could differ materially from those anticipated in these forward-looking statements for many
reasons, including those set forth under Item 1A Risk Factors in this Quarterly Report on Form
10-Q.
 Overview
 Changing the way cancer is treated ®
  ®
     13




---



##### Table of Contents



Critical Accounting Policies and the Use of Estimates
  Results of Operations
 Three and six months ended June 30, 2009 and 2008
 Revenue
  Revenue from Collaboration Agreement
  14




---



##### Table of Contents



Three Months Ended June 30,
    
    
    Six Months Ended June 30,2009
    
    
    2008
    
    
    2009
    
    
    2008(In thousands)
    
    
    (In thousands)Nexavar product revenue, net (as recorded by Bayer)
    
    $
    200,983
    
    
    $
    168,520
    
    
    $
    379,052
    
    
    $
    320,416Revenue subject to profit sharing (as recorded by
Bayer)
    
    $
    181,345
    
    
    $
    156,547
    
    
    $
    348,319
    
    
    $
    308,443Combined cost of goods sold, distribution,
selling, general and administrative expenses
    
    
    74,343
    
    
    
    80,135
    
    
    
    146,222
    
    
    
    142,838Combined collaboration commercial profit
    
    
    107,002
    
    
    
    76,412
    
    
    
    202,097
    
    
    
    165,605Onyxs share of collaboration commercial profit
    
    
    53,501
    
    
    
    38,206
    
    
    
    101,049
    
    
    
    82,803Reimbursement of Onyxs shared marketing expenses
    
    
    5,344
    
    
    
    6,028
    
    
    
    10,736
    
    
    
    10,286Royalty revenue
    
    
    1,374
    
    
    
    838
    
    
    
    2,151
    
    
    
    838Revenue from collaboration agreement
    
    $
    60,219
    
    
    $
    45,072
    
    
    $
    113,936
    
    
    $
    93,927
   Research and Development Expenses
  15




---



##### Table of Contents



Selling, General and Administrative Expenses
  Investment Income
  16




---



##### Table of Contents



Liquidity and Capital Resources
       Item 3. Quantitative and Qualitative Disclosures About Market Risk
 Interest Rate Risk
  17




---



##### Table of Contents



June 30, 2009
    
    December 31, 2008Average
    
    
    
    
    
    
    
    AverageFair Value
    
    Interest
    
    
    
    Fair Value
    
    InterestMaturity
    
    (In millions)
    
    Rate
    
    Maturity
    
    (In millions)
    
    RateCash equivalents, fixed rate
    
    0  2   months
    
    $
    73.0
    
    
    
    0.18
    %
    
    0  3   months
    
    $
    233.8
    
    
    
    0.53
    %Marketable securities, fixed rate
    
    0  12 months
    
    $
    394.1
    
    
    
    0.41
    %
    
    0  12 months
    
    $
    222.9
    
    
    
    0.87
    %
 Liquidity Risk
  Foreign Currency Exchange Rate Risk
   
 Item 4. Controls and Procedures
 Evaluation of Disclosure Controls and Procedures:
 18




---



##### Table of Contents



Changes in Internal Control over Financial Reporting:
 Inherent Limitations on Effectiveness of Controls:
 
 PART II: OTHER INFORMATION
 
 Item 1. Legal Proceedings.
 Onyx Pharmaceuticals, Inc.
v. Bayer Corporation and Bayer AG
 19




---



##### Table of Contents



Item 1A. Risk Factors.
 You should carefully consider the risks described below, together with all of the other information
included in this report, in considering our business and prospects. The risks and uncertainties
described below contain forward-looking statements, and our actual results may differ materially
from those discussed here. Additional risks and uncertainties not presently known to us or that we
currently deem immaterial also may impair our business operations. Each of these risk factors could
adversely affect our business, operating results and financial condition, as well as adversely
affect the value of an investment in our common stock.
 We have marked with an asterisk (*) those risk factors below that reflect material changes from the
risk factors included in our 2008 Annual Report on Form 10-K filed with the Securities and Exchange
Commission on February 25, 2009.
 Nexavar ® (sorafenib) tablets is our only approved product. If Nexavar fails and we are
unable to develop and commercialize alternative product candidates our business would fail.
  There are several competing therapies approved and in development for the treatment of advanced
kidney cancer. If Nexavar is unable to successfully compete against existing and future therapies
in advanced kidney cancer, our business would be harmed.*
    There are several existing approaches and several therapies in development for the treatment of
liver cancer. If Nexavar is unable to successfully compete against existing and future therapies in
liver cancer, our business would be harmed.*
  20




---



##### Table of Contents



Although Nexavar has been approved in the United States, the European Union and other territories
for the treatment of patients with liver cancer, adoption may be slow or limited for a variety of
reasons including the geographic distribution of the patient population, the current treatment
paradigm for liver cancer patients, the underlying liver disease present in most liver cancer
patients and limited reimbursement. If Nexavar is not broadly adopted for the treatment of liver
cancer, our business would be harmed.
   If our ongoing and planned clinical trials fail to demonstrate that Nexavar is safe and effective
or we are unable to obtain necessary regulatory approvals, we will be unable to expand the
commercial market for Nexavar and our business may fail.
     We are dependent upon our collaborative relationship with Bayer to further develop, manufacture and
commercialize Nexavar. There may be circumstances that delay or prevent Bayers ability to develop,
manufacture and commercialize Nexavar.
  21




---



##### Table of Contents




    
    adverse decisions by Bayer regarding the amount and timing of resource expenditures for
the development and commercialization of Nexavar;
    
    possible disagreements as to development plans, including clinical trials or regulatory
approval strategy;
    
    the right of Bayer to terminate the collaboration agreement with us on limited notice and
for reasons outside our control;
    
    loss of significant rights if we fail to meet our obligations under the collaboration
agreement;
    
    the development or acquisition by Bayer of competing products. For example, Bayer is
developing fluoro-sorafenib in Phase 2 clinical trials for kidney cancer and the ownership
of this compound is being disputed by us through the lawsuit we filed against Bayer;
    
    adverse regulatory or legal action against Bayer resulting from failure to meet
healthcare industry compliance requirements in the promotion, sale, or federal and state
reporting of Nexavar;
    
    changes in key management personnel at Bayer that are members of the collaborations
executive team; and
    
    disagreements with Bayer regarding the collaboration agreement or ownership of
proprietary rights.
    We face intense competition and rapid technological change, and many of our competitors have
substantially greater resources than we have.
  22




---



##### Table of Contents




    
    developing products;
    
    undertaking preclinical testing and human clinical trials;
    
    obtaining FDA and other regulatory approvals of products; and
    
    manufacturing and marketing products.
     Our operating results are unpredictable and may fluctuate. If our operating results are below the
expectations of securities analysts or investors, the trading price of our stock could decline.
   23




---



##### Table of Contents



The market may not accept our products and pharmaceutical pricing and reimbursement pressures may
reduce profitability.
    
    
    rate of adoption by healthcare practitioners;
    
    treatment guidelines issued by government and non-government agencies;
    
    types of cancer for which the product is approved;
    
    rate of a products acceptance by the target population;
    
    timing of market entry relative to competitive products;
    
    availability of alternative therapies;
    
    price of our product relative to alternative therapies;
    
    extent of marketing efforts by us and third-party distributors or agents retained by us;
and
    
    side effects or unfavorable publicity concerning our products or similar products.
  24




---



##### Table of Contents



Unstable market and economic conditions may have serious adverse consequences on our business.*
  Our clinical trials could take longer to complete than we project or may not be completed at all.
   If serious adverse side effects are associated with Nexavar, approval for Nexavar could be revoked,
sales of Nexavar could decline, and we may be unable to develop Nexavar as a treatment for other
types of cancer.
  25




---



##### Table of Contents



We are subject to extensive government regulation, which can be costly, time consuming and subject
us to unanticipated delays. If we are unable to obtain or maintain regulatory approvals for our
products, compounds or product candidates, we will not be able to market or further develop them.
      We are dependent on the efforts of Bayer to market and promote Nexavar.
    26




---



##### Table of Contents



We are dependent on the efforts of and funding by Bayer for the development of Nexavar.
  ONX 0801 may not be developed successfully, which would adversely affect our prospects for future
revenue growth and our stock price.
  
    
    preclinical tests may show the product to be toxic or lack efficacy in animal models;
    
    clinical trial results may show the product to be less effective than desired or to have
harmful or problematic side effects;
    
    the necessary regulatory approvals may not be received, or may be delayed due to factors
such as slow enrollment in clinical studies, extended length of time to achieve study
endpoints, additional time requirements for data analysis or preparation of the
investigational new drug application (IND), discussions with regulatory authorities,
requests from regulatory authorities for additional pre-clinical or clinical data, analyses
or changes to study design, or unexpected safety, efficacy or manufacturing issues;
    
    difficulties formulating the product, scaling the manufacturing process or in getting
approval for manufacturing;
    
    manufacturing costs, pricing or reimbursement issues, or other factors may make the
product uneconomical;
    
    the proprietary rights of others and their competing products and technologies may
prevent the product from being developed or commercialized; and
    
    the contractual rights of our collaborators or others may prevent the product from being
developed or commercialized.
  We do not have the manufacturing expertise or capabilities for any current and future products and
are dependent on others to fulfill our manufacturing needs, which could result in lost sales and
the delay of clinical trials or regulatory approval.
   27




---



##### Table of Contents



We have a history of losses, and we may continue to incur losses.*
   If we lose our key employees or are unable to attract or retain qualified personnel, our business
could suffer.
  We may need additional funds, and our future access to capital is uncertain.*
  
    
    revenue from our product sales;
    
    global product development and commercialization activities;
    
    the cost involved in enforcing patent claims against third parties and defending claims
by third parties;
    
    the costs associated with acquisitions or licenses of additional products;
    
    the cost of acquiring new or complementary businesses;
    
    competing technological and market developments;
    
    repayment of our of milestone-based advances to Bayer, and
    
    future fee and milestone payments to BTG and S*BIO.
 28




---



##### Table of Contents



We may not be able to realize the potential financial or strategic benefits of business
acquisitions or strategic investments, which could hurt our ability to grow our business, develop
new products or sell our products.*
  
    
    difficulty in combining the products, operations or workforce of any acquired business
with our business;
    
    difficulty in operating in a new or multiple new locations;
    
    disruption of our ongoing businesses or the ongoing business of the company that we
invest in or acquire;
    
    difficulty in realizing the potential financial or strategic benefits of the
transaction;
    
    difficulty in maintaining uniform standards, controls, procedures and policies;
    
    disruption of or delays in ongoing research and development efforts;
    
    diversion of capital and other resources;
    
    assumption of liabilities;
    
    diversion of resources and unanticipated expenses resulting from litigation arising
from potential or actual business acquisitions or investments;
    
    difficulties in entering into new markets in which we have limited or no experience and
where competitors in such markets have stronger positions; and
    
    impairment of relationships with our or the acquired businesses employees and other
third parties, such as suppliers, or the loss of such relationships as a result of our
acquisition or investment.
  29




---



##### Table of Contents



If the specialty pharmacies and distributors that we and Bayer rely upon to sell Nexavar fail to
perform, our business may be adversely affected.
  
    
    not provide us accurate or timely information regarding their inventories, the number
of patients who are using Nexavar or complaints about Nexavar;
    
    not effectively sell or support Nexavar;
    
    reduce their efforts or discontinue to sell or support Nexavar;
    
    not devote the resources necessary to sell Nexavar in the volumes and within the time
frames that we expect;
    
    be unable to satisfy financial obligations to us or others; and
    
    cease operations.
  We or Bayer may not be able to protect our intellectual property, which gives us the power to
exclude third parties from using Nexavar, or we may not be able to operate our business without
infringing upon the intellectual property rights of others.*
  
    
    obtain patents;
    
    license technology rights from others;
    
    protect trade secrets;
    
    operate without infringing upon the proprietary rights of others; and
    
    prevent others from infringing on our proprietary rights, particularly generic drug
manufacturers. In the United States, for drugs deemed a new chemical entity, such as
Nexavar, FDA regulations preclude the filing of an ANDA, that contains a challenge to the
patents, prior to the four year anniversary of marketing approval. As such, we expect that
one or more generic drug manufacturers will file an ANDA near the end of 2009, which will be
the four year anniversary of Nexavars United States marketing approval.
  30




---



##### Table of Contents



Limited foreign intellectual property protection and compulsory licensing could limit our revenue
opportunities.*
  31




---



##### Table of Contents



We may incur significant liability if it is determined that we are promoting the off-label use of
drugs or are otherwise found in violation of federal and state regulations in the United States or elsewhere.
   We face product liability risks and may not be able to obtain adequate insurance.*
   
    
    decreased demand for a product;
    
    injury to our reputation;
    
    withdrawal of clinical trial volunteers; and
    
    loss of revenues.
  If we do not receive timely and accurate financial information from Bayer regarding the development
and sale of Nexavar, we may be unable to accurately report our results of operations.
  32




---



##### Table of Contents



Provisions in our collaboration agreement with Bayer may prevent or delay a change in control.
  Our stock price is volatile.
  
    
    fluctuations in our results of operations;
    
    interim or final results of, or speculation about, clinical trials of Nexavar;
    
    development progress of our early stage compounds;
    
    decisions by regulatory agencies, or changes in regulatory requirements;
    
    ability to accrue patients into clinical trials;
    
    developments in our relationship with Bayer;
    
    public concern as to the safety and efficacy of our product candidates;
    
    changes in healthcare reimbursement policies;
    
    announcements by us or our competitors of technological innovations or new commercial
therapeutic products;
    
    government regulation;
    
    developments in patent or other proprietary rights or litigation brought against us;
    
    sales by us of our common stock or debt securities;
    
    foreign currency fluctuations, which would affect our share of collaboration profits or
losses; and
    
    general market conditions.
 Existing stockholders have significant influence over us.
   33




---



##### Table of Contents



A portion of our investment portfolio is invested in auction rate securities, and if auctions
continue to fail for amounts we have
invested, our investment will not be liquid. If the issuer of an auction rate security that we hold
is unable to successfully close future auctions and their credit rating deteriorates, we may be
required to adjust the carrying value of our investment through an impairment charge to earnings.
  We are at risk of securities class action litigation due to our expected stock price volatility.
  Our operating results could be adversely affected by product sales occurring outside the United
States and fluctuations in the value of the United States dollar against foreign currencies.
  Provisions in Delaware law, our charter and executive change of control agreements we have entered
into may prevent or delay a change of control.
  
    
    the board of directors approved the transaction where the stockholder acquired 15% or
more of the corporations stock;
    
    after the transaction in which the stockholder acquired 15% or more of the corporations
stock, the stockholder owned at least 85% of the corporations outstanding voting stock,
excluding shares owned by directors, officers and employee stock plans in which employee
participants do not have the right to determine confidentially whether shares held under the
plan will be tendered in a tender or exchange offer; or
    
    on or after this date, the merger or sale is approved by the board of directors and the
holders of at least two-thirds of the outstanding voting stock that is not owned by the
stockholder.
 34




---



##### Table of Contents




    
    our board is classified into three classes of directors as nearly equal in size as
possible with staggered three-year terms;
    
    the authority of our board to issue up to 5,000,000 shares of preferred stock and to
determine the price, rights, preferences and privileges of these shares, without stockholder
approval;
    
    all stockholder actions must be effected at a duly called meeting of stockholders and not
by written consent;
    
    special meetings of the stockholders may be called only by the chairman of the board, the
chief executive officer, the board or 10% or more of the stockholders entitled to vote at
the meeting; and
    
    no cumulative voting.
   
 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
  
 Item 3. Defaults Upon Senior Securities.
  
 Item 4. Submission of Matters to a Vote of Security Holders.
  (a)
    
    All of the nominees of the Board of Directors were elected to serve
until our annual meeting of stockholders in 2012. The nominees were:
Paul Goddard, Ph.D.; 36,269,224 common shares for, none against and
16,325,429 withheld; Antonio J. Grillo-López, M.D.; 52,159,269 common
shares for, none against and 435,384 withheld; and Wendell Wierenga,
Ph.D.; 51,557,115 common shares for, none against and 1,037,538
withheld. The term of office of directors Corinne H. Lyle and Thomas
Wiggans continues until our annual meeting of stockholders in 2010.
The term of office of directors Magnus Lundberg and N. Anthony Coles,
M.D. continues until our annual meeting of stockholders in 2011.
 35




---



##### Table of Contents



(b)
    
    The stockholders approved the amendment to the Companys 2005 Equity
Incentive Plan (Incentive Plan): 37,862,980 common shares for,
6,398,549 against, 56,978 abstaining. The amendment affected the
following changes to the Incentive Plan:
 
    
    the number of authorized shares available for issuance under
the Incentive Plan was increased by 2,000,000 shares; and
 
    
    the rate at which the Incentive Plans share reserve will be
reduced was changed to 1.6 shares (from the prior rate of 1.3 shares)
for each share granted pursuant to stock purchase awards, stock bonus
awards, stock unit awards and other stock awards, as well as for
options and stock appreciation rights granted with exercise prices
that are less than 100% of the fair market value of our common stock
on the date of grant.
 (c)
    
    The stockholders ratified the selection by the Audit Committee of the
Board of Directors of Ernst &Young LLP as our independent registered
public accounting firm for our fiscal year ending December 31, 2009:
50,494,510 common shares for, 2,087,250 against and 12,893 abstaining.
 
 Item 5. Other Information.
  
 Item 6. Exhibits.
 3.1 (1)
    
    Restated Certificate of Incorporation of the Company.3.2 (2)
    
    Amended and Restated Bylaws of the Company.3.3 (3)
    
    Certificate of Amendment to Amended and Restated Certificate of Incorporation.3.4 (4)
    
    Certificate of Amendment to Amended and Restated Certificate of Incorporation.4.1
    
    Reference is made to Exhibits 3.1, 3.2, 3.3 and 3.4.4.2 (1)
    
    Specimen Stock Certificate.10.13(i)(5) +
    
    2005 Equity Incentive Plan, as amended.31.1 (6)
    
    Certification of Chief Executive Officer as required by Rule 13a-14(a) or
Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.31.2 (6)
    
    Certification of Chief Financial Officer as required by Rule 13a-14(a) or
Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.32.1 (6)
    
    Certifications required by Rule 13a-14(b) or Rule 15d-14(b) of the Securities
Exchange Act of 1934, as amended, and Section 1350 of Chapter 63 of Title 18
of the United States Code (18 U.S.C. 1350).
 36




---



##### Table of Contents



+
    
    Management contract or compensatory plan.(1)
    
    Filed as an exhibit to the Companys Registration Statement on Form SB-2 (No. 333-3176-LA).(2)
    
    Filed as an exhibit to Companys Current Report on Form 8-K filed on December 5, 2008.(3)
    
    Filed as an exhibit to the Companys Quarterly Report on Form 10-Q for the quarter ended June
30, 2000.(4)
    
    Filed as an exhibit to the Companys Registration Statement on Form S-3 (No. 333-134565)
filed on May 30, 2006.(5)
    
    Filed as an exhibit to the Companys Current Report on Form 8-K filed on May 27, 2009.(6)
    
    This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is
not deemed filed with the Securities and Exchange Commission and is not to be incorporated by
reference into any filing of Onyx Pharmaceuticals, Inc. under the Securities Act of 1933, as
amended or the Securities Exchange Act of 1934, as amended (whether made before or after the
date of the Quarterly Report on Form 10-Q), irrespective of any general incorporation language
contained in such filing. 37




---



##### Table of Contents



SIGNATURES
  ONYX PHARMACEUTICALS, INC.Date: August 4, 2009
    By:
    /s/  N. Anthony ColesN. Anthony ColesPresident and Chief Executive Officer

(Principal Executive Officer)Date: August 4, 2009
    By:
    /s/  Matthew K. FustMatthew K. FustExecutive Vice President and Chief Financial Officer

(Principal Financial and Accounting Officer) 38




---



##### Table of Contents



EXHIBIT INDEX
 3.1 (1)
    
    Restated Certificate of Incorporation of the Company.3.2 (2)
    
    Amended and Restated Bylaws of the Company.3.3 (3)
    
    Certificate of Amendment to Amended and Restated Certificate of Incorporation.3.4 (4)
    
    Certificate of Amendment to Amended and Restated Certificate of Incorporation.4.1
    
    Reference is made to Exhibits 3.1, 3.2, 3.3 and 3.4.4.2 (1)
    
    Specimen Stock Certificate.10.13(i)(5)+
    
    2005 Equity Incentive Plan, as amended.31.1 (6)
    
    Certification of Chief Executive Officer as required by Rule 13a-14(a) or
Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.31.2 (6)
    
    Certification of Chief Financial Officer as required by Rule 13a-14(a) or
Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.32.1 (6)
    
    Certifications required by Rule 13a-14(b) or Rule 15d-14(b) of the Securities
Exchange Act of 1934, as amended, and Section 1350 of Chapter 63 of Title 18
of the United States Code (18 U.S.C. 1350).
 
 +
    
    Management contract or compensatory plan.(1)
    
    Filed as an exhibit to the Companys Registration Statement on Form SB-2 (No. 333-3176-LA).(2)
    
    Filed as an exhibit to the Companys Current Report on Form 8-K filed on December 5, 2008.(3)
    
    Filed as an exhibit to the Companys Quarterly Report on Form 10-Q for the quarter ended June
30, 2000.(4)
    
    Filed as an exhibit to the Companys Registration Statement on Form S-3 (No. 333-134565)
filed on May 30, 2006.(5)
    
    Filed as an exhibit to the Companys Current Report on Form 8-K filed on May 27, 2009.(6)
    
    This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is
not deemed filed with the Securities and Exchange Commission and is not to be incorporated by
reference into any filing of Onyx Pharmaceuticals, Inc. under the Securities Act of 1933, as
amended or the Securities Exchange Act of 1934, as amended (whether made before or after the
date of the Quarterly Report on Form 10-Q), irrespective of any general incorporation language
contained in such filing. 39